Welcome to our dedicated page for Windtree Therapeutics news (Ticker: WINT), a resource for investors and traders seeking the latest updates and insights on Windtree Therapeutics stock.
Windtree Therapeutics, Inc. (WINT) generates news across biotechnology, licensing, financing and corporate diversification activities. Company press releases highlight its evolution from a biotechnology focus into a diversified business with several divisions and an emphasis on becoming a revenue generating company. For followers of WINT news, this means updates can span drug development milestones, asset sales, licensing income opportunities, environmental services initiatives, fintech transactions and capital markets activity.
In the biotech arena, Windtree’s news flow has included interim data and scientific presentations for its cardiovascular drug candidate istaroxime and related SERCA2a activators, as well as decisions to adjust or terminate specific clinical studies based on resources and strategic priorities. The company has also reported on strengthening its patent estate for these cardiovascular assets and later announced an agreement to sell its cardiovascular drug candidates to Seismic Pharmaceutical Holdings, LLC while retaining rights to a share of future proceeds and transferring certain development payables.
Windtree’s communications also cover its acute pulmonary franchise, where a global license agreement for RDS treatments such as SURFAXIN, lyophilized lucinactant and AEROSURF may generate milestone and royalty payments if development and commercialization progress under the licensee. Additional news items describe corporate strategy decisions, including a focus on environmental services and other revenue generating businesses, a letter of intent to acquire CommLoan, Inc. in the fintech and commercial real estate lending technology space, and the outcome of stockholder votes supporting financing flexibility.
Investors tracking WINT-related headlines will also see coverage of financing arrangements, preferred stock conversions, equity line of credit structures, and the company’s exploration of a BNB cryptocurrency treasury strategy, as well as its transition from the Nasdaq Capital Market to over-the-counter trading. Bookmarking this news feed can help readers monitor how Windtree’s mix of biotech assets, licensing agreements and diversified business initiatives evolves over time.
Windtree Therapeutics (WINT) announced positive results from its Phase 2 istaroxime study for early cardiogenic shock, published in the European Journal of Heart Failure. The SEISMiC study showed that istaroxime significantly improved systolic blood pressure and cardiac function without worsening renal function. These findings support istaroxime's potential as a treatment for cardiogenic shock, a condition with high mortality rates and limited effective therapies. Windtree plans to optimize dosing and is set to discuss the next Phase 3 program with the FDA.
Windtree Therapeutics (WINT) has announced a late-breaking abstract presentation for its Phase 2 clinical study of istaroxime, targeting early cardiogenic shock, at the Heart Failure Society of America's Annual Meeting on October 2. The SEISMiC study demonstrated significant improvement in systolic blood pressure within the first 6 hours and maintained benefits through 24 hours. Patients showed enhanced stroke volume and cardiac output without increased heart rate, with no worsening of renal function. Cardiogenic shock represents a market valued at $1.25 billion, highlighting the urgent need for innovative treatments.
Windtree Therapeutics, Inc. (NasdaqCM: WINT) announced that CEO Craig Fraser will present a corporate overview and hold one-on-one meetings at the Ladenburg Thalmann Healthcare Conference on September 29, 2022, at the Sofitel Hotel, New York, NY. The presentation will take place at 4:00 p.m. ET. Investors can also access a live webcast and replay on the company's Investor Relations website. Windtree focuses on late-stage interventions for acute cardiovascular disorders, including treatments like istaroxime for heart failure and other innovative compounds.
Windtree Therapeutics (NasdaqCM: WINT) announced that CEO Craig Fraser will present a corporate overview and hold virtual 1x1 meetings at the H.C. Wainwright 24th Annual Global Investment Conference from September 12-14, 2022. The presentation will be available on demand starting September 12 at 7:00 am ET. Windtree focuses on late-stage interventions for acute cardiovascular disorders, particularly developing the first-in-class treatment, istaroxime, for acute heart failure. The company also has a portfolio that includes rostafuroxin for genetically targeted hypertensive patients.
Windtree Therapeutics (NasdaqCM: WINT) has entered a global licensing agreement with Lee’s Pharmaceutical and Zhaoke Pharmaceutical for the development of its KL4 surfactant and AEROSURF® treatments for respiratory distress syndrome in preterm infants. The agreement could yield up to $78.9 million in milestones and low double-digit royalties. Lee’s and Zhaoke will cover all development costs, relieving Windtree of ongoing expenses related to the KL4 platform, thereby enhancing its financial position for core programs, particularly istaroxime for acute heart failure.
Windtree Therapeutics (NasdaqCM: WINT) reported its Q2 2022 financial results, highlighting a significant operating loss reduction to $17.5 million from $45.4 million in Q2 2021. The company achieved notable success with its Phase 2 SEISMiC study of istaroxime, demonstrating improved systolic blood pressure and cardiac function in early cardiogenic shock patients. The SEISMiC study's results have drawn positive industry interest, prompting the company to begin Phase 3 study preparations and explore licensing discussions for strategic partnerships. Windtree expects its cash runway to support operations into Q1 2023.
Windtree Therapeutics (NasdaqCM: WINT) announced positive clinical results for istaroxime in treating early cardiogenic shock, supporting a new development program. With a market potential of $1.25 billion, there is a strong demand for innovative therapies in this area. Following the promising Phase 2 SEISMiC study results, the company is engaged in discussions for partnerships and licensing opportunities to enhance shareholder value. Windtree aims to optimize resources and reduce costs while advancing istaroxime's development, focusing on creating a faster, cost-effective pathway.
Windtree Therapeutics (WINT) announced positive results from its Phase 2 study of istaroxime for early cardiogenic shock, presented at the European Society of Cardiology Heart Failure Meeting. The study met its primary endpoint, demonstrating a significant improvement in systolic blood pressure (SBP) at 6 hours compared to the control group, persisting at 24 hours. Notable secondary endpoints were also achieved, showing enhancements in cardiac function and renal maintenance. The company plans to advance the istaroxime program, aiming for further studies and regulatory discussions.
Windtree Therapeutics, Inc. (WINT) announced a conference call on May 23, 2022, to discuss the positive topline results of its Phase 2 study of istaroxime in treating early cardiogenic shock, following a late-breaking presentation at the European Society of Cardiology Heart Failure Meeting. Management will share additional findings on blood pressure changes, cardiac function, and safety measures. Cardiogenic shock, with high mortality rates, represents a significant unmet medical need, anticipating a market value of $1.25 billion. Istaroxime shows promise as a dual mechanism therapy to enhance cardiac function.
Windtree Therapeutics, Inc. (WINT) announced positive topline results from its Phase 2 SEISMiC study of istaroxime for early cardiogenic shock, showing significant improvement in systolic blood pressure compared to controls. The results will be presented at the ESC Heart Failure Conference on May 23, 2022. For Q1 2022, the company reported an operating loss of $8.3 million and a net loss of $8.1 million ($0.29 per share), an improvement from $9.0 million in Q1 2021. Cash and cash equivalents stand at $15.5 million, providing a runway into Q1 2023.
FAQ
What is the current stock price of Windtree Therapeutics (WINT)?
What is the market cap of Windtree Therapeutics (WINT)?
